H. Gevorkyan

发表

The novel BACE inhibitor MK-8931 dramatically lowers CSF beta-amyloid in patients with mild-to-moderate Alzheimer's disease

M. Forman, L. Ereshefsky, O. Laterza, 2013, Alzheimer's & Dementia.

A randomized, placebo-controlled, single ascending-dose study to assess the safety, tolerability, pharmacokinetics, and immunogenicity of subcutaneous tralokinumab in Japanese healthy volunteers.

R. Faggioni, E. Piper, D. She, 2017, Drug metabolism and pharmacokinetics.

Peripheral and central nervous system inhibition of 11β-hydroxysteroid dehydrogenase type 1 in man by the novel inhibitor ABT-384

G. Marek, D. Barnes, L. Ereshefsky, 2013, Translational Psychiatry.

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor

J. Xie, T. Macek, M. Tsai, 2016, Psychopharmacology.

Safety and pharmacokinetic profiles of MGS0274 besylate (TS‐134), a novel metabotropic glutamate 2/3 receptor agonist prodrug, in healthy subjects

Brian Marcy, S. Chaki, S. Okuyama, 2020, British journal of clinical pharmacology.

First‐in‐Human Study of the Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of E6742, a Dual Antagonist of Toll‐like Receptors 7 and 8, in Healthy Volunteers

J. Aluri, S. Hojo, Y. Kitahara, 2022, Clinical pharmacology in drug development.

Remyelination therapy goes to trial for multiple sclerosis

Mike P. Wattjes, Frederik Barkhof, Soma Ray, 2014, Neurology: Neuroimmunology & Neuroinflammation.

BACE inhibitor LY2886721 safety and central and peripheral PK and PD in healthy subjects (HSs)

R. Dean, M. Citron, L. Ereshefsky, 2012, Alzheimer's & Dementia.

The effect of LCZ696 (sacubitril/valsartan) on amyloid‐β concentrations in cerebrospinal fluid in healthy subjects

P. Pal, T. Langenickel, I. Rajman, 2015, British journal of clinical pharmacology.

Safety, pharmacokinetics and quantitative EEG modulation of TAK‐071, a novel muscarinic M1 receptor positive allosteric modulator, in healthy subjects

D. Buhl, F. Mamashli, A. Simen, 2021, British journal of clinical pharmacology.

Randomized Placebo-Controlled Trial Evaluating the Ophthalmic Safety of Single-Dose Tafenoquine in Healthy Volunteers

J. Slakter, D. Barañano, R. Sergott, 2019, Drug Safety.

A phase 1 study of the safety, tolerability, pharmacokinetics, and pharmacodynamics of TAK-063, a selective PDE10A inhibitor

T. Macek, M. Tsai, H. Gevorkyan, 2016, Psychopharmacology.